Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

The effect of oral sucrose on exercise tolerance in patients with McArdle's disease.

Vissing J, Haller RG.

N Engl J Med. 2003 Dec 25;349(26):2503-9.

2.

Effect of oral sucrose shortly before exercise on work capacity in McArdle disease.

Andersen ST, Haller RG, Vissing J.

Arch Neurol. 2008 Jun;65(6):786-9. doi: 10.1001/archneur.65.6.786.

PMID:
18541798
3.

The effect of oral sucrose on exercise tolerance in patients with McArdle's disease.

O'Reilly DS.

Ann Clin Biochem. 2004 May;41(Pt 3):255. No abstract available.

PMID:
15154396
4.

Oral sucrose and exercise tolerance in McArdle's disease.

Gaglia JL, Wolfsdorf JI.

N Engl J Med. 2004 Apr 8;350(15):1575-6; author reply 1575-6. No abstract available.

5.

Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose.

Ørngreen MC, Olsen DB, Vissing J.

Neurology. 2002 Oct 8;59(7):1046-51.

PMID:
12370460
6.

A diagnostic cycle test for McArdle's disease.

Vissing J, Haller RG.

Ann Neurol. 2003 Oct;54(4):539-42.

PMID:
14520671
7.

Metabolism of branched-chain amino acids and ammonia during exercise: clues from McArdle's disease.

Wagenmakers AJ, Coakley JH, Edwards RH.

Int J Sports Med. 1990 May;11 Suppl 2:S101-13. Review.

PMID:
2193889
8.

A double blind, placebo controlled, crossover trial of D-ribose in McArdle's disease.

Steele IC, Patterson VH, Nicholls DP.

J Neurol Sci. 1996 Mar;136(1-2):174-7.

PMID:
8815168
9.

No spontaneous second wind in muscle phosphofructokinase deficiency.

Haller RG, Vissing J.

Neurology. 2004 Jan 13;62(1):82-6.

PMID:
14718702
10.

Pharmacological and nutritional treatment for McArdle's disease (Glycogen Storage Disease type V).

Quinlivan R, Beynon RJ.

Cochrane Database Syst Rev. 2004;(3):CD003458. Review. Update in: Cochrane Database Syst Rev. 2008;(2):CD003458.

PMID:
15266486
11.

Sweet success--a treatment for McArdle's disease.

Amato AA.

N Engl J Med. 2003 Dec 25;349(26):2481-2. No abstract available.

PMID:
14695407
12.

Exercise capacity in a 78 year old patient with McArdle's disease: it is never too late to start exercising.

Perez M, Martin MA, Rubio JC, Maté-Muñoz JL, Gómez-Gallego F, Foster C, Andreu AL, Arenas J, Lucia A, Fleck SJ.

Br J Sports Med. 2006 Aug;40(8):725-6; discussion 726.

13.

Oral branched-chain amino acids do not improve exercise capacity in McArdle disease.

MacLean D, Vissing J, Vissing SF, Haller RG.

Neurology. 1998 Nov;51(5):1456-9.

PMID:
9818881
14.

Exercise intolerance in patients with McArdle's disease or mitochondrial myopathies.

Chaussain M, Camus F, Defoligny C, Eymard B, Fardeau M.

Eur J Med. 1992 Dec;1(8):457-63.

PMID:
1341204
15.

Exercise tolerance and daily life in McArdle's disease.

Ollivier K, Hogrel JY, Gomez-Merino D, Romero NB, Laforêt P, Eymard B, Portero P.

Muscle Nerve. 2005 May;31(5):637-41.

PMID:
15614801
16.

Myophosphorylase deficiency impairs muscle oxidative metabolism.

Haller RG, Lewis SF, Cook JD, Blomqvist CG.

Ann Neurol. 1985 Feb;17(2):196-9.

PMID:
3856415
18.

Tricarboxylic acid cycle intermediates during incremental exercise in healthy subjects and in patients with McArdle's disease.

Sahlin K, Jorfeldt L, Henriksson KG, Lewis SF, Haller RG.

Clin Sci (Lond). 1995 Jun;88(6):687-93.

PMID:
7634753
19.

Depot-glucagon in the treatment of McArdle's disease.

Day TJ, Mastaglia FL.

Aust N Z J Med. 1985 Dec;15(6):748-50.

PMID:
3869441
20.

Oxygen consumption is increased relative to work rate in patients with McArdle's disease.

O'Dochartaigh CS, Ong HY, Lovell SM, Riley MS, Patterson VH, Young IS, Nicholls DP.

Eur J Clin Invest. 2004 Nov;34(11):731-7.

PMID:
15530145

Supplemental Content

Support Center